Aims This review aims to evaluate the feasibility of robot-assisted laparoscopic surgery (RALS) as an alternative to standard laparoscopic surgery (SLS) for the treatment of bowel deep-infiltrative endometriosis. Additionally, it aims to provide guidance for future study design, by gaining insight into the current state of research, in accordance with the IDEAL framework. Method Systematic review was conducted to identify relevant studies on RALS for bowel DIE in Medline, Embase, Cochrane Library, and PubMed databases up to August 2023. Following PRISMA guidelines, 11 primary studies were identified, encompassing 364 RALS patients and 83 SLS patients, from which surgical details, operative and postoperative outcomes were extracted. PROSPERO Registration: CRD42022308611 Results In the RALS group, mean operating time was longer (235 ± 112 min) than in the standard laparoscopy group (171 ± 76 min) (p < 0.01). However, RALS resulted in fewer postoperative complications (10.1%) compared to standard laparoscopy (26.5%), with a comparable major complication rate, as well as a shorter hospital stay (5.3 ± 3.5 days vs. 7.3 ± 4.1 days) (p < 0.01). Available evidence for RALS in bowel DIE was rated IDEAL Stage 2b, indicating feasibility and safety for advancing to randomized controlled trials (RCTs). Conclusion RALS is a safe and feasible alternative to standard laparoscopy for bowel endometriosis treatment, potentially improving rates of intraoperative and overall postoperative complications despite longer operating times. The research landscape contains predominantly observational and comparative studies, in line with IDEAL Stage 2b. More robust RCTs are required to further establish the potential advantages of RALS in treatment of DIE.